Skip to main content

Table 3 Follow-up data of HIV infected children in HIV clinics at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia from April 1 to May 15, 2018 (n = 318)

From: Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia

Variables   N (%)
Status Category
 Alive on ART 318 (92.4)
 Dead 26 (7.6)
Duration of follow up(month)
  ≤ 36 13 (4.1)
 37–59 31 (9.7)
  ≥ 60 274 (86.2)
Substitution of first line
 Yes 162 (50.9)
  Treatment failure 72 (44.4)
  New drug available 50 (30.8)
  Toxicity 23 (14.1)
  Drug stock out 6 (3.7)
  Change to fixed dose 6 (3.7)
  New TB diagnosis 2 (1.23)
  Others 3 (1.85)
 No 156 (49.05)
Time taken to initiate second line medication
  < 4 weeks 26 (36.1)
  ≥ 5 weeks 46 (63.8)
Adherence status of past 6 month
 Good 269 (84.5)
 Fair 37 (11.6)
 Poor 12 (3.7)
WHO T stage
 T1 289 (90.8)
 T2 7 (2.2)
 T3 1 (0.31)
 T4 21 (6.6)
Current CD4 count
 Not-significant immunosuppression 241(75.8)
 Mild-immunosuppression 49 (15.4)
 Advanced-immunosuppression 17 (5.3)
 Severe-immunosuppression 11 (3.5)
Viral load test
 Undetectable 268 (84.2)
  ≥ 150 24 (7.5)
 Missing data 26 (8.1)
Developed treatment failure to first line
 Yes 72 (22.6)
 Clinical failure only 2 2.7
 Immunological failure only 37 (51.3)
 Virologic failure only 6 (8.3)
 Clinical and immunological 24 (33.3)
 Virologic and immunologic 3 (4.17)
 No 246 (77.4)